Leerink Partners Forecasts Strong Price Appreciation for Viridian Therapeutics (NASDAQ:VRDN) Stock

Key Points

• Leerink Partners raised its price target on Viridian Therapeutics to $54 from $50 and reiterated its “outperform” rating, implying 87.25% upside from the reported share price.
• Analyst sentiment is broadly positive: 11 analysts rate the stock Buy and one rates it Sell, with a consensus price target of $41. Wedbush, Wells Fargo and Truist also recently increased their targets and maintained bullish ratings.
• Viridian reported a quarterly loss of $0.81 per share, narrower than analysts expected, while revenue of $25.75 million topped the $4.72 million consensus. The company remains loss-making.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) had its price target increased by equities research analysts at Leerink Partners from $50.00 to $54.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has an "outperform" rating on the stock. Leerink Partners's price objective suggests a potential upside of 87.25% from the stock's current price.

A number of other equities analysts have also weighed in on the company. Wedbush increased their target price on Viridian Therapeutics from $41.00 to $42.00 and gave the stock an "outperform" rating in a research note on Thursday. Wells Fargo & Company boosted their price target on Viridian Therapeutics from $31.00 to $34.00 and gave the company an "overweight" rating in a research note on Thursday. Truist Financial upped their price objective on Viridian Therapeutics from $39.00 to $42.00 and gave the company a "buy" rating in a report on Thursday. Wall Street Zen cut Viridian Therapeutics from a "sell" rating to a "strong sell" rating in a research report on Sunday, October 4th. Finally, Royal Bank Of Canada lifted their target price on Viridian Therapeutics from $36.00 to $38.00 and gave the stock an "outperform" rating in a report on Tuesday, September 22nd. Eleven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $41.00.

Viridian Therapeutics Stock Performance

Shares of VRDN stock traded down $0.22 during midday trading on Thursday, hitting $28.84. 2,414,244 shares of the company were exchanged, compared to its average volume of 2,154,895. The firm has a market capitalization of $3.27 billion, a P/E ratio of -8.55 and a beta of 1.07. The company has a debt-to-equity ratio of 0.43, a quick ratio of 16.95 and a current ratio of 16.95. The firm's 50 day moving average price is $21.80 and its two-hundred day moving average price is $21.85. Viridian Therapeutics has a 52 week low of $13.18 and a 52 week high of $34.29.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.02) by $0.21. Viridian Therapeutics had a negative net margin of 505.86% and a negative return on equity of 72.97%. The firm had revenue of $25.75 million during the quarter, compared to the consensus estimate of $4.72 million. As a group, equities research analysts anticipate that Viridian Therapeutics will post -4.07 earnings per share for the current year.

Insider Buying and Selling

In other Viridian Therapeutics news, insider Jennifer Tousignant sold 14,212 shares of Viridian Therapeutics stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $24.50, for a total value of $348,194.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 2.40% of the stock is currently owned by company insiders.

Institutional Trading of Viridian Therapeutics

Several large investors have recently modified their holdings of the stock. Knights of Columbus Asset Advisors LLC lifted its stake in Viridian Therapeutics by 27.6% during the third quarter. Knights of Columbus Asset Advisors LLC now owns 90,019 shares of the company's stock worth $1,853,000 after purchasing an additional 19,466 shares during the last quarter. 71 West Capital Partners increased its stake in shares of Viridian Therapeutics by 4.1% in the 3rd quarter. 71 West Capital Partners now owns 22,282 shares of the company's stock valued at $459,000 after purchasing an additional 882 shares during the last quarter. Fulcrum Asset Management LLP bought a new position in shares of Viridian Therapeutics in the 3rd quarter valued at $97,000. Pictet Asset Management Holding SA raised its holdings in shares of Viridian Therapeutics by 13.5% during the 3rd quarter. Pictet Asset Management Holding SA now owns 12,741 shares of the company's stock worth $262,000 after buying an additional 1,516 shares in the last quarter. Finally, AlphaCentric Advisors LLC acquired a new position in shares of Viridian Therapeutics during the 3rd quarter worth $216,000.

Key Headlines Impacting Viridian Therapeutics

Here are the key news stories impacting Viridian Therapeutics this week:

• Positive Sentiment: Four firms raised their targets and maintained bullish ratings: Truist lifted its target to $42, Wells Fargo to $34, Wedbush to $42, and HC Wainwright to $40. Needham also raised its target to $38. These upgrades point to continued analyst optimism. Truist rating Wells Fargo rating Wedbush rating HC Wainwright rating Needham rating
• Positive Sentiment: Viridian reported a third-quarter loss of $0.81 per share, narrower than analysts’ roughly $1.01–$1.02 estimate, and revenue of $25.75 million versus a $4.72 million consensus. The earnings and revenue beats may support confidence in its progress. Q3 results
• Positive Sentiment: Viridian is targeting broad coverage for its Lumvoa launch in six to nine months and expects to submit an elegrobart biologics license application in the first quarter of 2027. These commercial and regulatory milestones could provide near-term catalysts, though execution remains important. Lumvoa and elegrobart update
• Negative Sentiment: Despite beating estimates, the quarterly loss widened from $0.34 per share a year earlier to $0.81, underscoring that Viridian remains loss-making. A separate commentary also argued the stock may be overvalued even with its new launch, raising valuation concerns after recent optimism. Valuation commentary

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for serious autoimmune diseases. The company's lead research area is thyroid eye disease (TED), a debilitating condition that can cause eye inflammation, swelling, pain and vision-related complications.

Viridian's pipeline is centered on antibodies designed to inhibit the insulin-like growth factor-1 receptor (IGF-1R), a target associated with TED. Its investigational therapies include veligrotug (VRDN-001), an intravenous treatment candidate, and VRDN-003, a subcutaneous formulation being developed to provide a more convenient administration option.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.